China NMPA Drug Inspection - GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. - Lamivudine tablets

China NMPA drug inspection for GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd. published October 31, 2019. Drug: Lamivudine tablets. The Hubei Provincial Food and Drug Administration issued its Fourth Quarter 2012 "Hubei Provincial Drug Quality Bulletin

View on Dashboard

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd.

Inspection Date

Unknown Date

Product Type

ID: 925a0fc7-321a-427f-980e-f0a4d6097739

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox